Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
159.37(c) 158.13(c) 157.89(c) 160.65(c) 160.3(c) Last
7 068 176 6 903 189 6 643 065 10 030 794 7 600 260 Volume
-0.42% -0.78% -0.15% +1.75% -0.22% Change
More quotes
Financials (USD)
Sales 2020 81 734 M - -
Net income 2020 15 924 M - -
Net Debt 2020 5 979 M - -
P/E ratio 2020 26,3x
Yield 2020 2,47%
Sales 2021 88 400 M - -
Net income 2021 18 337 M - -
Net cash position 2021 2 259 M - -
P/E ratio 2021 22,6x
Yield 2021 2,64%
Capitalization 422 B 422 B -
EV / Sales 2020 5,24x
EV / Sales 2021 4,75x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
01/26Earnings Release
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
01/15JOHNSON & JOHNSON : DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Become..
PU
01/15GENMAB A/S : to Receive $30 Million Milestone Payment from Janssen Over FDA Appr..
MT
01/15"MY 2021 HEALTHCARE RESOLUTION" : 7 Johnson & Johnson Leaders Share Their Goals ..
PU
01/14JOHNSON & JOHNSON : Statement on Political Contributions
PU
01/14NEXTECH AR : sees $7.3M in business for Q4
AQ
01/14US Stocks Rise in Early Trading Amid Expectations of Surge in Consumer Spendi..
MT
01/14Presidency On Africa Centres for Disease Control and Prevention Securing Firs..
AQ
01/14The earnings season picks up steam
01/14THE COVID-19 DATA PLAN : 3 Innovative Ways Johnson & Johnson Is Using Data Scien..
AQ
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14270 Million Covid-19 Vaccine Doses Secured for Africa
AQ
01/13JOHNSON & JOHNSON : Favorable Data Published About Johnson & Johnson Covid-19 Va..
DJ
01/13MARKET CHATTER : Johnson & Johnson One Dose Covid-19 Vaccine Shown to Be Safe, G..
MT
01/13JOHNSON & JOHNSON : Shares Higher After-Hours - One-Dose Covid-19 Vaccine Report..
MT
01/13JOHNSON & JOHNSON : COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published..
PU
More news
News in other languages on JOHNSON & JOHNSON
01/14J&J : publication des données du candidat vaccin à la Covid19
01/14L'inflation revient au centre du jeu
01/14EN DIRECT DES MARCHES : Renault, Peugeot, Carrefour, Marie Brizard, Intel, Baidu..
01/13Les valeurs à suivre aujourd'hui à Wall Street Mercredi 13 janvier 2020
01/13JOHNSON & JOHNSON : des retards dans la production de son vaccin contre le Covid
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 165,78 $
Last Close Price 160,30 $
Spread / Highest target 12,9%
Spread / Average Target 3,42%
Spread / Lowest Target -13,3%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120